
    
      The drug being tested in this survey is called vedolizumab for IV infusion 300 mg. This drug
      is being tested to treat patients who have CD.

      This survey is an observational (non-interventional) study and will look at the long-term
      safety and effectiveness of vedolizumab for IV infusion 300 mg in the routine clinical
      setting. The planned number of observed patients will be approximately 300.

      This multi-center observational trial will be conducted in Japan.
    
  